Literature DB >> 1387301

Absolute bioavailability of clarithromycin after oral administration in humans.

S Y Chu1, R Deaton, J Cavanaugh.   

Abstract

The absolute bioavailability of clarithromycin, a new macrolide antimicrobial agent, was assessed in a three-way, randomized, single-dose, crossover study conducted with 22 healthy volunteers, 19 of whom provided analyzable study data. The bioavailability parameters of two 250-mg oral tablet formulations were calculated with reference to an identical dose administered by intravenous infusion of the lactobionate salt. After adjustment for formulation potency, the mean absolute bioavailabilities of the two oral formulations were 52 and 55%, on the basis of the appearance of parent compound in the systemic circulation. Metabolite peak concentration and area under the plasma concentration-time curve data after oral dosing were generally greater than those after intravenous infusion, suggesting that marked first-pass metabolism of clarithromycin occurs after oral administration. Pharmacokinetic analysis of the parent drug and the active 14-hydroxy metabolite data suggests complete (or nearly complete) absorption of the drug after oral administration.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1387301      PMCID: PMC188854          DOI: 10.1128/AAC.36.5.1147

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

1.  In-vitro activity of clarithromycin (A-56268; TE-031) against gram-positive bacteria.

Authors:  K Rolston; G Gooch; D Ho
Journal:  J Antimicrob Chemother       Date:  1989-03       Impact factor: 5.790

2.  Simultaneous determination of clarithromycin and 14(R)-hydroxyclarithromycin in plasma and urine using high-performance liquid chromatography with electrochemical detection.

Authors:  S Y Chu; L T Sennello; R C Sonders
Journal:  J Chromatogr       Date:  1991-11-15

3.  CSTRIP, a fortran IV computer program for obtaining initial polyexponential parameter estimates.

Authors:  A J Sedman; J G Wagner
Journal:  J Pharm Sci       Date:  1976-07       Impact factor: 3.534

4.  The area under the curve of metabolites for drugs and metabolites cleared by the liver and extrahepatic organs. Its dependence on the administration route of precursor drug.

Authors:  P J Klippert; J Noordhoek
Journal:  Drug Metab Dispos       Date:  1985 Jan-Feb       Impact factor: 3.922

5.  Metabolite pharmacokinetics: the area under the curve of metabolite and the fractional rate of metabolism of a drug after different routes of administration for renally and hepatically cleared drugs and metabolites.

Authors:  K S Pang
Journal:  J Pharmacokinet Biopharm       Date:  1981-08

6.  Activities of clarithromycin, sulfisoxazole, and rifabutin against Mycobacterium avium complex multiplication within human macrophages.

Authors:  C Perronne; A Gikas; C Truffot-Pernot; J Grosset; J J Pocidalo; J L Vilde
Journal:  Antimicrob Agents Chemother       Date:  1990-08       Impact factor: 5.191

7.  In vitro activity of tosufloxacin (A-60969) and clarithromycin (A-56268, TE-031) against resistant Haemophilus influenzae, Streptococcus pneumoniae and Branhamella catarrhalis isolates.

Authors:  J P Bryan; C Waters; J Sheffield; K F Wagner
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-05       Impact factor: 3.267

8.  Enhancement of the in vitro and in vivo activities of clarithromycin against Haemophilus influenzae by 14-hydroxy-clarithromycin, its major metabolite in humans.

Authors:  D J Hardy; R N Swanson; R A Rode; K Marsh; N L Shipkowitz; J J Clement
Journal:  Antimicrob Agents Chemother       Date:  1990-07       Impact factor: 5.191

9.  Metabolism and disposition of clarithromycin in man.

Authors:  J L Ferrero; B A Bopp; K C Marsh; S C Quigley; M J Johnson; D J Anderson; J E Lamm; K G Tolman; S W Sanders; J H Cavanaugh
Journal:  Drug Metab Dispos       Date:  1990 Jul-Aug       Impact factor: 3.922

10.  Comparative antimycobacterial activities of difloxacin, temafloxacin, enoxacin, pefloxacin, reference fluoroquinolones, and a new macrolide, clarithromycin.

Authors:  E A Gorzynski; S I Gutman; W Allen
Journal:  Antimicrob Agents Chemother       Date:  1989-04       Impact factor: 5.191

View more
  24 in total

1.  Pharmacokinetics of single- and multiple-dose oral clarithromycin in soft tissues determined by microdialysis.

Authors:  Friederike Traunmüller; Markus Zeitlinger; Petra Zeleny; Markus Müller; Christian Joukhadar
Journal:  Antimicrob Agents Chemother       Date:  2007-07-02       Impact factor: 5.191

2.  Clarithromycin increases neuronal excitability in CA3 pyramidal neurons through a reduction in GABAergic signaling.

Authors:  Edyta K Bichler; Courtney C Elder; Paul S García
Journal:  J Neurophysiol       Date:  2016-10-12       Impact factor: 2.714

Review 3.  Clarithromycin. A review of its efficacy in the treatment of respiratory tract infections in immunocompetent patients.

Authors:  H D Langtry; R N Brogden
Journal:  Drugs       Date:  1997-06       Impact factor: 9.546

4.  Clarithromycin, Midazolam, and Digoxin: Application of PBPK Modeling to Gain New Insights into Drug-Drug Interactions and Co-medication Regimens.

Authors:  Daniel Moj; Nina Hanke; Hannah Britz; Sebastian Frechen; Tobias Kanacher; Thomas Wendl; Walter Emil Haefeli; Thorsten Lehr
Journal:  AAPS J       Date:  2016-11-07       Impact factor: 4.009

Review 5.  Clinical pharmacokinetics of clarithromycin.

Authors:  K A Rodvold
Journal:  Clin Pharmacokinet       Date:  1999-11       Impact factor: 6.447

Review 6.  Ketolides--the modern relatives of macrolides : the pharmacokinetic perspective.

Authors:  Markus Zeitlinger; Claudia Christina Wagner; Birgit Heinisch
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

7.  Clarithromycin therapy of experimental Treponema pallidum infections in hamsters.

Authors:  J Alder; K Jarvis; M Mitten; N L Shipkowitz; P Gupta; J Clement
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

8.  High rate of erythromycin and clarithromycin resistance among Streptococcus pneumoniae isolates from blood cultures from Providence, R.I.

Authors:  J R Lonks; A A Medeiros
Journal:  Antimicrob Agents Chemother       Date:  1993-09       Impact factor: 5.191

Review 9.  Clarithromycin clinical pharmacokinetics.

Authors:  F Fraschini; F Scaglione; G Demartini
Journal:  Clin Pharmacokinet       Date:  1993-09       Impact factor: 6.447

Review 10.  Clarithromycin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential.

Authors:  D H Peters; S P Clissold
Journal:  Drugs       Date:  1992-07       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.